Shinichi Fukuhara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shinichi Fukuhara has a total of 302 co-authors. Here are the top co-authors by number of shared publications:
G. Michael Deeb
Department of Cardiac Surgery, University of Michigan, Ann Arbor, USA
19 shared publicationsHimanshu J. Patel
Department of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan, USA
15 shared publicationsBo Yang
Department of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan, USA
13 shared publicationsGorav Ailawadi
Department of Cardiac Surgery, University of Michigan, Ann Arbor, Mich
12 shared publications- Toshiki Kuno
Harvard Medical School
9 shared publications Karen M. Kim
Department of Cardiac Surgery, University of Michigan, Ann Arbor, Mich
8 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by AME Publishing Company in Journal of Visualized Surgery
- Vol. 12, 51
Management of aortic stenosis: lifetime management is a moving target
Management of aortic stenosis: lifetime management is a moving target
- 1 September 2026
- Published by AME Publishing Company in Journal of Visualized Surgery
- Vol. 12, 51
Open AccessManagement of aortic stenosis: lifetime management is a moving target
Management of aortic stenosis: lifetime management is a moving target
- 21 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (14) , e049636
Comparison of Outcomes of Leadless Versus Transvenous Pacemakers Following Tricuspid Valve Surgery
Background: Transvenous pacemaker implantation after tricuspid valve surgery may cause adverse outcomes due to lead–valve interactions. Although leadless pacemakers may mitigate these risks, empirical data remain limited. Methods: We compared outcomes of leadless versus transvenous pacemakers following tricuspid surgery using a target trial emulation framework. We analyzed Medicare beneficiaries aged ≥65 years who underwent tricuspid valve surgery and received a pacemaker during the index admission between 2017 and 2021, using propensity score matching weight analysis to control for confounders. Primary outcomes were in‐hospital death and 2‐year heart failure hospitalization. Secondary outcomes included 2‐year death. Results: We included 185 and 1336 patients in the leadless and transvenous groups, respectively. Use of leadless pacemakers increased from 6.3% in 2017 to 17.5% in 2021. Leadless pacemaker recipients more often underwent tricuspid valve replacement (29.2% versus 8.5%) while concomitant mitral surgery was less common (69.2% versus 86.8%). After adjustment, we found no evidence that in‐hospital death (adjusted odds ratio, 1.82 [95% CI, 0.65–5.13] for leadless) and 2‐year heart failure hospitalizations (subdistribution hazard ratio [HR], 0.88 [95% CI, 0.60–1.30] for leadless) differed between the 2 groups. We also found no evidence that 2‐year death (adjusted HR, 1.04 [95% CI, 0.69–1.57] for leadless) differed between groups. Conclusions: No statistically significant differences were detected between leadless versus transvenous pacemaker implantations after tricuspid valve surgery. However, CIs were wide, and a clinically meaningful difference in either direction cannot be excluded. The study may therefore be underpowered, and the absence of echocardiographic data limits assessment of tricuspid regurgitation, warranting prospective studies.
- 21 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (14) , e049636
Comparison of Outcomes of Leadless Versus Transvenous Pacemakers Following Tricuspid Valve Surgery
Background: Transvenous pacemaker implantation after tricuspid valve surgery may cause adverse outcomes due to lead–valve interactions. Although leadless pacemakers may mitigate these risks, empirical data remain limited. Methods: We compared outcomes of leadless versus transvenous pacemakers following tricuspid surgery using a target trial emulation framework. We analyzed Medicare beneficiaries aged ≥65 years who underwent tricuspid valve surgery and received a pacemaker during the index admission between 2017 and 2021, using propensity score matching weight analysis to control for confounders. Primary outcomes were in‐hospital death and 2‐year heart failure hospitalization. Secondary outcomes included 2‐year death. Results: We included 185 and 1336 patients in the leadless and transvenous groups, respectively. Use of leadless pacemakers increased from 6.3% in 2017 to 17.5% in 2021. Leadless pacemaker recipients more often underwent tricuspid valve replacement (29.2% versus 8.5%) while concomitant mitral surgery was less common (69.2% versus 86.8%). After adjustment, we found no evidence that in‐hospital death (adjusted odds ratio, 1.82 [95% CI, 0.65–5.13] for leadless) and 2‐year heart failure hospitalizations (subdistribution hazard ratio [HR], 0.88 [95% CI, 0.60–1.30] for leadless) differed between the 2 groups. We also found no evidence that 2‐year death (adjusted HR, 1.04 [95% CI, 0.69–1.57] for leadless) differed between groups. Conclusions: No statistically significant differences were detected between leadless versus transvenous pacemaker implantations after tricuspid valve surgery. However, CIs were wide, and a clinically meaningful difference in either direction cannot be excluded. The study may therefore be underpowered, and the absence of echocardiographic data limits assessment of tricuspid regurgitation, warranting prospective studies.
- 1 June 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (6) , e016068
Impact of TAVR Failure Mechanism on Outcomes After Reintervention: From the EXPLANTORREDO-TAVR Registry
BACKGROUND: As transcatheter aortic valve replacement (TAVR) expands to patients with longer life expectancy, the impact of failure mechanisms on outcomes of TAVR-explant and redo-TAVR remains uncertain. We sought to evaluate outcomes of TAVR reintervention based on the failure mechanism of the index transcatheter aortic valve. METHODS: From 2009 to 2022, 553 patients from 29 centers in the EXPLANTORREDO-TAVR registry (Explant or Redo Transcatheter Aortic Valve Replacement) underwent TAVR-explant or redo-TAVR for transcatheter aortic valve failure. Patients with endocarditis were excluded. Patients with structural valve deterioration (SVD, N=224 [64.9%]) were compared with those with nonstructural valve dysfunction (NSVD, N=121 [35.1%]), comprising paravalvular leak (86.0%) and prosthesis-patient mismatch (14.0%). Outcomes were assessed at 30 days and 1 year. RESULTS: Mean age was 75.6±9.3 years, with 42% women. There were no differences in reintervention type between groups (redo-TAVR in 58.0% SVD versus 49.6% NSVD; TAVR-explant: 42.0% versus 50.4%; P =0.14). Compared with NSVD, SVD was the predominant mode of failure in balloon-expandable valves (50.7% versus 24.8%; P P P =0.003). Mortality at 30 days and 1 year did not differ significantly between SVD and NSVD for either redo-TAVR (30 days: 3.2% versus 1.7%, P =1.00; 1 year: 18.0% versus 12.0%; P =0.47) or TAVR-explant (30 days: 16.3% versus 12.1%, P =0.63; 1 year: 40.0% versus 29.5%; P =0.39). There were also no differences in risk-adjusted 3-year cumulative mortality between groups (redo-TAVR: hazard ratio, 1.30 [95% CI, 0.68–2.46], P =0.43 [ref=NSVD]; TAVR-explant: hazard ratio, 1.24 [95% CI, 0.64–2.41]; P =0.53). CONCLUSIONS: SVD and NSVD failures had distinct valve types and reintervention timing, with SVD having a longer time to TAVR reintervention, but the failure mechanism did not impact reintervention type or clinical outcomes.
- 1 June 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (6) , e016068
Impact of TAVR Failure Mechanism on Outcomes After Reintervention: From the EXPLANTORREDO-TAVR Registry
BACKGROUND: As transcatheter aortic valve replacement (TAVR) expands to patients with longer life expectancy, the impact of failure mechanisms on outcomes of TAVR-explant and redo-TAVR remains uncertain. We sought to evaluate outcomes of TAVR reintervention based on the failure mechanism of the index transcatheter aortic valve. METHODS: From 2009 to 2022, 553 patients from 29 centers in the EXPLANTORREDO-TAVR registry (Explant or Redo Transcatheter Aortic Valve Replacement) underwent TAVR-explant or redo-TAVR for transcatheter aortic valve failure. Patients with endocarditis were excluded. Patients with structural valve deterioration (SVD, N=224 [64.9%]) were compared with those with nonstructural valve dysfunction (NSVD, N=121 [35.1%]), comprising paravalvular leak (86.0%) and prosthesis-patient mismatch (14.0%). Outcomes were assessed at 30 days and 1 year. RESULTS: Mean age was 75.6±9.3 years, with 42% women. There were no differences in reintervention type between groups (redo-TAVR in 58.0% SVD versus 49.6% NSVD; TAVR-explant: 42.0% versus 50.4%; P =0.14). Compared with NSVD, SVD was the predominant mode of failure in balloon-expandable valves (50.7% versus 24.8%; P P P =0.003). Mortality at 30 days and 1 year did not differ significantly between SVD and NSVD for either redo-TAVR (30 days: 3.2% versus 1.7%, P =1.00; 1 year: 18.0% versus 12.0%; P =0.47) or TAVR-explant (30 days: 16.3% versus 12.1%, P =0.63; 1 year: 40.0% versus 29.5%; P =0.39). There were also no differences in risk-adjusted 3-year cumulative mortality between groups (redo-TAVR: hazard ratio, 1.30 [95% CI, 0.68–2.46], P =0.43 [ref=NSVD]; TAVR-explant: hazard ratio, 1.24 [95% CI, 0.64–2.41]; P =0.53). CONCLUSIONS: SVD and NSVD failures had distinct valve types and reintervention timing, with SVD having a longer time to TAVR reintervention, but the failure mechanism did not impact reintervention type or clinical outcomes.
- Open Access
- 24 March 2026
- Published by Elsevier in JTCVS Techniques
- Vol. 37, 102325
Warm aortic arch repair: Redefining proximal aortic arch surgery
- 24 March 2026
- Published by Elsevier in JTCVS Techniques
- Vol. 37, 102325
Open AccessWarm aortic arch repair: Redefining proximal aortic arch surgery
- Open Access
- 20 March 2026
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
Mid-term outcomes after aortic valve repair with the internal geometric annuloplasty ring
- 20 March 2026
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
Open AccessMid-term outcomes after aortic valve repair with the internal geometric annuloplasty ring
- Open Access
- 25 February 2026
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 41 (4)
Free Versus In situ Right Internal Mammary Artery as a Conduit in Coronary Artery Bypass Surgery: A Meta-Analysis
Objectives: There is debate regarding the optimal choice for a second conduit in coronary artery bypass grafting. The right internal mammary artery (RIMA) is commonly employed as a second conduit; however, it is unclear whether the free (fRIMA) or in situ (isRIMA) configuration yields superior outcomes. We performed a systematic review and meta-analysis to compare clinical outcomes between fRIMA and isRIMA as the second conduit. Methods: A comprehensive search of PubMed (MEDLINE), EMBASE, and CENTRAL was performed through May 2025 to identify studies comparing outcomes in patients undergoing coronary artery bypass grafting with either fRIMA or isRIMA as a second conduit. The outcomes of interest were overall mortality, graft occlusion, major adverse cardiac events (MACE), and repeat revascularization. Data with 95% confidence intervals (CIs) were extracted. Pooled analysis was performed using a random-effects model. Results: A total of 13 studies with 9899 patients were included (fRIMA, n = 3095; isRIMA, n = 6804). The median study follow-up duration ranged from 1 to 20 years across the studies. No statistically significant differences were observed in overall mortality (hazard ratio [95% CI] = 1.16 [0.79-1.69]), graft occlusion (1.04 [0.90-1.21]), MACE (0.87 [0.62-1.21]), and repeat revascularization (1.34 [0.68-2.66]). Conclusions: In this meta-analysis, no statistically significant differences were observed between fRIMA and isRIMA configurations across the evaluated clinical outcomes. These findings suggest that, within the limitations of available evidence, the choice between fRIMA and isRIMA may be guided by clinical context, surgeon preference, patient anatomy, and target vessel characteristics rather than expected differences in major clinical outcomes.
- 25 February 2026
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 41 (4)
Open AccessFree Versus In situ Right Internal Mammary Artery as a Conduit in Coronary Artery Bypass Surgery: A Meta-Analysis
Objectives: There is debate regarding the optimal choice for a second conduit in coronary artery bypass grafting. The right internal mammary artery (RIMA) is commonly employed as a second conduit; however, it is unclear whether the free (fRIMA) or in situ (isRIMA) configuration yields superior outcomes. We performed a systematic review and meta-analysis to compare clinical outcomes between fRIMA and isRIMA as the second conduit. Methods: A comprehensive search of PubMed (MEDLINE), EMBASE, and CENTRAL was performed through May 2025 to identify studies comparing outcomes in patients undergoing coronary artery bypass grafting with either fRIMA or isRIMA as a second conduit. The outcomes of interest were overall mortality, graft occlusion, major adverse cardiac events (MACE), and repeat revascularization. Data with 95% confidence intervals (CIs) were extracted. Pooled analysis was performed using a random-effects model. Results: A total of 13 studies with 9899 patients were included (fRIMA, n = 3095; isRIMA, n = 6804). The median study follow-up duration ranged from 1 to 20 years across the studies. No statistically significant differences were observed in overall mortality (hazard ratio [95% CI] = 1.16 [0.79-1.69]), graft occlusion (1.04 [0.90-1.21]), MACE (0.87 [0.62-1.21]), and repeat revascularization (1.34 [0.68-2.66]). Conclusions: In this meta-analysis, no statistically significant differences were observed between fRIMA and isRIMA configurations across the evaluated clinical outcomes. These findings suggest that, within the limitations of available evidence, the choice between fRIMA and isRIMA may be guided by clinical context, surgeon preference, patient anatomy, and target vessel characteristics rather than expected differences in major clinical outcomes.
- Open Access
- 16 November 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 121 (5) , 1069-1079
One-Year Results of Novel Aortic Arch Hybrid Prosthesis for Repair of Acute DeBakey Type I Dissection With Malperfusion: PERSEVERE Study
- 16 November 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 121 (5) , 1069-1079
Open AccessOne-Year Results of Novel Aortic Arch Hybrid Prosthesis for Repair of Acute DeBakey Type I Dissection With Malperfusion: PERSEVERE Study
- 4 September 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 121 (4) , 1027-1028
When Surgery Is Possible, Transcatheter Mitral Valve Replacement Should Not Be Plan A
- 4 September 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 121 (4) , 1027-1028
When Surgery Is Possible, Transcatheter Mitral Valve Replacement Should Not Be Plan A
- Open Access
- 20 August 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (1) , 101-109
Challenging the transcatheter-first paradigm: Redo surgical aortic valve replacement after previous transcatheter or surgical aortic valve replacement
- 20 August 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 171 (1) , 101-109
Open AccessChallenging the transcatheter-first paradigm: Redo surgical aortic valve replacement after previous transcatheter or surgical aortic valve replacement